Literature DB >> 8424428

Natural course of chronic hepatitis C.

M Takahashi1, G Yamada, R Miyamoto, T Doi, H Endo, T Tsuji.   

Abstract

We studied 333 chronic hepatitis C patients to evaluate the natural course of this disease. Among 57 patients undergoing serial biopsies, 20 had chronic persistent hepatitis (CPH) at the first biopsy, and 10 of them progressed to chronic active hepatitis (CAH) or liver cirrhosis (LC) after 11 yr. Sixteen patients had CAH 2A, and this progressed to CAH 2B or LC in 10 cases over 9 yr. Among the 21 patients with CAH 2B, progression to LC was noted in 15 after 7 yr. Among the 100 patients observed for over 5 yr, the normalization of liver function for at least 3 yr was seen in only four patients. In two of these four patients, serum HCV-RNA was tested serially. Despite the sustained normalization of alanine aminotransferase levels, HCV-RNA continued to be detectable in one patient. We conclude that many patients with chronic hepatitis C eventually show progression of their disease after a long and symptomless course.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424428

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  28 in total

Review 1.  Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management.

Authors:  V P Choudhry; S K Acharya
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

2.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Clinical sequelae of hepatitis C acquired from injection drug use.

Authors:  M J Tong; N S el-Farra
Journal:  West J Med       Date:  1996-05

Review 4.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

5.  Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C.

Authors:  W G Bennett; S G Pauker; G L Davis; J B Wong
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

6.  Short-term versus sustained response to interferon therapy: effect on histology.

Authors:  O Reichard
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 7.  Patterns of progression: unpredictability and risk of decompensated cirrhosis.

Authors:  N C Tassopoulos
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 8.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

9.  The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha.

Authors:  D Palmović; I Kurelac; J Crnjaković-Palmović
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

10.  Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon.

Authors:  G Scotto; M Grimaldi
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.